Pennsylvania--(Marketwire - October 8, 2007) -
PuriCore Receives US Patent on Wound Therapy Method
Hypochlorous Acid Invention Shown to Enhance Wound Healing
STAFFORD, UK, October 8, 2007-PuriCore (LSE: PURI), the life sciences
company focused on the control of infectious pathogens, today announces
that the US Patent and Trademark Office has granted US Patent No.
7,276,255, entitled Wound and Ulcer Treatment with Super-Oxidized Water
relating to wound therapy methods. PuriCore's methods employ hypochlorous
acid at neutral or near-neutral pH to enhance the healing process for
wounds. Related patents have been approved previously for PuriCore's
technology in the UK and Europe.
PuriCore's invention is broadly drawn to methods of treating any open
wound with hypochlorous acid solutions at neutral or near-neutral pH
including two important processes, reducing wound bioburden and promoting
tissue repair. Research data submitted with the patent shows that
PuriCore's invention method provides an optimum wound-healing environment
by decreasing the bioburden of harmful microorganisms within the wound
and by promoting skin cell proliferation and re-growth.
Greg Bosch, CEO of PuriCore, said:
"Our research indicates that hypochlorous acid solutions represent a new
and effective class of treatment for hard-to-heal wounds," "The granting
of this first US patent specific for wound therapy complements our broad
intellectual property portfolio focused on antimicrobial solutions and
devices for producing these solutions."
For further information please contact:
PuriCore +1 (484) 321 2700
Keith Goldan
Financial Dynamics +44 207 269 7169
Ben Brewerton / John Gilbert
Notes to editors
About PuriCore's Wound Therapy Solution
PuriCore's patented wound therapy technology is being commercialized as
the Vashe™ Wound Therapy System, a novel, noninvasive, easy-to-use
wound management process that has been shown to be complementary to
existing treatment methods. The Vashe System is an FDA-cleared medical
device used for moistening, irrigating, cleaning, and debriding acute and
chronic wounds including stage I through IV pressure ulcers, stasis
ulcers, diabetic ulcers, post-surgical wounds, first and second degree
burns, abrasions, and minor irritations of the skin. The Vashe Solution
mimics the human body's own infection fighter, hypochlorous acid. Recent
and ongoing clinical case studies show that the Vashe Solution eliminates
pathogens that produce harmful toxins and odor and cause significant
pain, without any damage to tissue. Research to date demonstrates that
the Vashe Solution provides a safe and effective alternative to cytotoxic
antimicrobial and antiseptic products currently used to treat infected
wounds and surgical sites and is an important element in the overall
clinical process of effective wound management.
About PuriCore
PuriCore (London Stock Exchange: PURI) is a life sciences company focused
on developing and commercializing proprietary products that safely,
effectively, and naturally kill contagious pathogens. PuriCore's
technology provides a solution to a broad range of markets that depend
upon controlling contamination, including food safety, medical device
disinfection, wound therapy, and hospitality. The Company's proprietary
technology mimics the human body's production of the natural
antimicrobial hypochlorous acid, which is highly effective in killing
bacteria, viruses, and fungal spores. Deploying hypochlorous acid
solutions as soaks, sprays, mists, and in other forms, PuriCore's
technology is designed to limit the spread of infectious disease,
including major public health threats of M. tuberculosis, MRSA, E.coli,
norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and
Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with
offices in Stafford, UK.
To receive additional information on PuriCore, please visit our web site
at
www.puricore.com, which does not form part of this press release.
This information is provided by RNS
The company news service from the London Stock Exchange